Format

Send to

Choose Destination
Sci Rep. 2016 Nov 30;6:37070. doi: 10.1038/srep37070.

TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling.

Author information

1
The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Shanghai 200438, China.
2
Department of Health Statistics, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
3
Department of Microbiology, Shanghai Key Laboratory of Medical Biodefense, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
4
Department of Oncology, Shanghai Tongren Hospital, Shanghai Jiaotong University, 1111 Xianxia Road, Shanghai 200336, China.
5
Department of Medical Oncology, Jinling Hospital, 305 Zhongshan East Road, Nanjing, Jiangsu 210000, China.
6
Department of Computer Science, Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY, 12180, United States.

Abstract

Transmembrane p24 trafficking protein 3(TMED3) is a metastatic suppressor in colon cancer, but its function in the progression of hepatocellular carcinoma (HCC) is unknown. Here, we report that TMED3 was up-regulated in HCC and portal vein tumor thrombus. TMED3 up-regulation in HCC was significantly correlated with aggressive characteristics and predicted poor prognosis in HCC patients. TMED3 overexpression in HCC cell lines promoted cell migration and invasion. In contrast, TMED3 knockdown suppressed HCC metastasis both in vitro and in vivo. Gene microarray analysis revealed decreased IL-11 expression in TMED3-knockdown cells. We propose that TMED3 promotes HCC metastasis through IL-11/STAT3 signaling. Taken together, these findings demonstrate that TMED3 promotes HCC metastasis and is a potential prognostic biomarker in HCC.

PMID:
27901021
PMCID:
PMC5128793
DOI:
10.1038/srep37070
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center